A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This protocol is for a lead-in safety study of 5 patients followed by a randomized Phase 2
clinical trial of BMX-001, a new class of pharmaceutical, in 64 patients with multiple brain
metastases (MBM) undergoing whole brain radiation therapy (WBRT). Preliminary studies have
demonstrated that BMX-001 provides protection of normal tissues from radiation-induced injury
and augments tumor growth inhibition.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
BioMimetix JV, LLC
Collaborators:
Duke Cancer Institute National Cancer Institute (NCI)